Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1995-11

AUTHORS

Pierre Fiset, Hendrikus L.M. Lemmens, Talmage E. Egan, Steven L. Shafer, Donald R. Stanski

ABSTRACT

The purpose of this study was to model pharmacodynamically the reversal of midazolam sedation with flumazenil. Ten human volunteers underwent four different sessions. In session 1, individual midazolam pharmacokinetics and electroencephalographic pharmacodynamics were determined. In sessions 2 and 3, a computer-controlled infusion of midazolam with individual volunteer pharmacokinetic data was administered, targeting a plasma concentration corresponding to a light or deep level of sedation (20% or 80% of the maximal midazolam electroencephalographic effect) for a period of 210 minutes. After obtaining a stable electroencephalographic effect and constant midazolam plasma concentrations, a zero-order infusion of flumazenil was started until complete reversal of midazolam electroencephalographic effect was obtained. The flumazenil infusion was then stopped and the volunteer was allowed to resedate because of the constant midazolam drug effect. The electroencephalographic response was measured during a 180-minute period and analyzed by aperiodic analysis and fast-Fourier transforms. In session 4, a midazolam plasma concentration corresponding to a deep level of sedation was targeted for 210 minutes to examine for the possible development of acute tolerance. No flumazenil was given in session 4. For a light sedation level, with a mean midazolam plasma concentration of 160 +/- 64 ng/ml, the mean half-life of the equilibration rate constant of flumazenil reversal is 5.0 +/- 2.5 minutes, and the mean effect site concentration causing 50% of Emax is 13.7 +/- 5.8 ng/ml. For a deep level of sedation, with a mean midazolam plasma concentration of 551 +/- 196 ng/ml, the mean half-life of the equilibration rate constant is 3.9 +/- 1.5 minutes, and the mean effect site concentration causing 50% of Emax is 20.6 +/- 6.8 ng/ml. This study provides an estimate of the magnitude of the blood/central nervous system equilibration delay for flumazenil antagonism of midazolam sedation and further defines the usefulness of the electroencephalogram as a measure of midazolam pharmacodynamic effect. More... »

PAGES

567-582

Identifiers

URI

http://scigraph.springernature.com/pub.10.1016/0009-9236(95)90177-9

DOI

http://dx.doi.org/10.1016/0009-9236(95)90177-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1035614341

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/7586951


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Electroencephalography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Flumazenil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fourier Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "GABA Modulators", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypnotics and Sedatives", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Midazolam", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Biological", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Utah Department of Anesthesia Salt Lake City Utah.", 
          "id": "http://www.grid.ac/institutes/grid.223827.e", 
          "name": [
            "McGill University Department of Anesthesia Montreal Quebec Canada", 
            "Stanford University Department of Anesthesia", 
            "Palo Alto Veterans Administration Medical Center Palo Alto Calif.", 
            "University of Utah Department of Anesthesia Salt Lake City Utah."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fiset", 
        "givenName": "Pierre", 
        "id": "sg:person.01352532122.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352532122.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Utah Department of Anesthesia Salt Lake City Utah.", 
          "id": "http://www.grid.ac/institutes/grid.223827.e", 
          "name": [
            "McGill University Department of Anesthesia Montreal Quebec Canada", 
            "Stanford University Department of Anesthesia", 
            "Palo Alto Veterans Administration Medical Center Palo Alto Calif.", 
            "University of Utah Department of Anesthesia Salt Lake City Utah."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lemmens", 
        "givenName": "Hendrikus L.M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Utah Department of Anesthesia Salt Lake City Utah.", 
          "id": "http://www.grid.ac/institutes/grid.223827.e", 
          "name": [
            "McGill University Department of Anesthesia Montreal Quebec Canada", 
            "Stanford University Department of Anesthesia", 
            "Palo Alto Veterans Administration Medical Center Palo Alto Calif.", 
            "University of Utah Department of Anesthesia Salt Lake City Utah."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Egan", 
        "givenName": "Talmage E.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Utah Department of Anesthesia Salt Lake City Utah.", 
          "id": "http://www.grid.ac/institutes/grid.223827.e", 
          "name": [
            "McGill University Department of Anesthesia Montreal Quebec Canada", 
            "Stanford University Department of Anesthesia", 
            "Palo Alto Veterans Administration Medical Center Palo Alto Calif.", 
            "University of Utah Department of Anesthesia Salt Lake City Utah."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shafer", 
        "givenName": "Steven L.", 
        "id": "sg:person.01053425453.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053425453.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Utah Department of Anesthesia Salt Lake City Utah.", 
          "id": "http://www.grid.ac/institutes/grid.223827.e", 
          "name": [
            "McGill University Department of Anesthesia Montreal Quebec Canada", 
            "Stanford University Department of Anesthesia", 
            "Palo Alto Veterans Administration Medical Center Palo Alto Calif.", 
            "University of Utah Department of Anesthesia Salt Lake City Utah."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stanski", 
        "givenName": "Donald R.", 
        "id": "sg:person.0727474353.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727474353.23"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf01080874", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022518677", 
          "https://doi.org/10.1007/bf01080874"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1988.106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006636807", 
          "https://doi.org/10.1038/clpt.1988.106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-199120060-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042979892", 
          "https://doi.org/10.2165/00003088-199120060-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-199018030-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045679441", 
          "https://doi.org/10.2165/00003088-199018030-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01620551", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005966643", 
          "https://doi.org/10.1007/bf01620551"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1989.41", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044118057", 
          "https://doi.org/10.1038/clpt.1989.41"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01064422", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020922126", 
          "https://doi.org/10.1007/bf01064422"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-198814010-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045191439", 
          "https://doi.org/10.2165/00003088-198814010-00001"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-199120060-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047792911", 
          "https://doi.org/10.2165/00003088-199120060-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/clpt.1994.174", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009681062", 
          "https://doi.org/10.1038/clpt.1994.174"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1995-11", 
    "datePublishedReg": "1995-11-01", 
    "description": "The purpose of this study was to model pharmacodynamically the reversal of midazolam sedation with flumazenil. Ten human volunteers underwent four different sessions. In session 1, individual midazolam pharmacokinetics and electroencephalographic pharmacodynamics were determined. In sessions 2 and 3, a computer-controlled infusion of midazolam with individual volunteer pharmacokinetic data was administered, targeting a plasma concentration corresponding to a light or deep level of sedation (20% or 80% of the maximal midazolam electroencephalographic effect) for a period of 210 minutes. After obtaining a stable electroencephalographic effect and constant midazolam plasma concentrations, a zero-order infusion of flumazenil was started until complete reversal of midazolam electroencephalographic effect was obtained. The flumazenil infusion was then stopped and the volunteer was allowed to resedate because of the constant midazolam drug effect. The electroencephalographic response was measured during a 180-minute period and analyzed by aperiodic analysis and fast-Fourier transforms. In session 4, a midazolam plasma concentration corresponding to a deep level of sedation was targeted for 210 minutes to examine for the possible development of acute tolerance. No flumazenil was given in session 4. For a light sedation level, with a mean midazolam plasma concentration of 160 +/- 64 ng/ml, the mean half-life of the equilibration rate constant of flumazenil reversal is 5.0 +/- 2.5 minutes, and the mean effect site concentration causing 50% of Emax is 13.7 +/- 5.8 ng/ml. For a deep level of sedation, with a mean midazolam plasma concentration of 551 +/- 196 ng/ml, the mean half-life of the equilibration rate constant is 3.9 +/- 1.5 minutes, and the mean effect site concentration causing 50% of Emax is 20.6 +/- 6.8 ng/ml. This study provides an estimate of the magnitude of the blood/central nervous system equilibration delay for flumazenil antagonism of midazolam sedation and further defines the usefulness of the electroencephalogram as a measure of midazolam pharmacodynamic effect.", 
    "genre": "article", 
    "id": "sg:pub.10.1016/0009-9236(95)90177-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1017409", 
        "issn": [
          "0009-9236", 
          "1532-6535"
        ], 
        "name": "Clinical Pharmacology & Therapeutics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "58"
      }
    ], 
    "keywords": [
      "midazolam plasma concentrations", 
      "mean effect site concentration", 
      "plasma concentrations", 
      "effect site concentration", 
      "electroencephalographic effects", 
      "midazolam sedation", 
      "lighter sedation levels", 
      "computer-controlled infusion", 
      "session 4", 
      "zero-order infusion", 
      "flumazenil infusion", 
      "midazolam pharmacokinetics", 
      "sedation level", 
      "flumazenil reversal", 
      "equilibration rate constant", 
      "pharmacodynamic effects", 
      "acute tolerance", 
      "healthy volunteers", 
      "flumazenil antagonism", 
      "sedation", 
      "drug effects", 
      "equilibration delay", 
      "flumazenil", 
      "pharmacokinetic data", 
      "pharmacodynamic modeling", 
      "human volunteers", 
      "infusion", 
      "aperiodic analysis", 
      "electroencephalographic responses", 
      "volunteers", 
      "midazolam", 
      "complete reversal", 
      "session 1", 
      "session 2", 
      "minutes", 
      "site concentration", 
      "Emax", 
      "different sessions", 
      "levels", 
      "pharmacodynamics", 
      "pharmacokinetics", 
      "possible development", 
      "period", 
      "effect", 
      "reversal", 
      "antagonism", 
      "concentration", 
      "study", 
      "electroencephalogram", 
      "sessions", 
      "response", 
      "fast-Fourier transform", 
      "rate", 
      "measures", 
      "tolerance", 
      "usefulness", 
      "purpose", 
      "data", 
      "development", 
      "delay", 
      "analysis", 
      "equilibration rate", 
      "magnitude", 
      "estimates", 
      "deep levels", 
      "rate constants", 
      "modeling", 
      "constants", 
      "transform", 
      "individual midazolam pharmacokinetics", 
      "electroencephalographic pharmacodynamics", 
      "individual volunteer pharmacokinetic data", 
      "volunteer pharmacokinetic data", 
      "stable electroencephalographic effect", 
      "constant midazolam plasma concentrations", 
      "midazolam electroencephalographic effect", 
      "constant midazolam drug effect", 
      "midazolam drug effect", 
      "mean midazolam plasma concentration", 
      "blood/central nervous system equilibration delay", 
      "central nervous system equilibration delay", 
      "nervous system equilibration delay", 
      "system equilibration delay", 
      "midazolam pharmacodynamic effect"
    ], 
    "name": "Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam", 
    "pagination": "567-582", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1035614341"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1016/0009-9236(95)90177-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "7586951"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1016/0009-9236(95)90177-9", 
      "https://app.dimensions.ai/details/publication/pub.1035614341"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_266.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1016/0009-9236(95)90177-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1016/0009-9236(95)90177-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1016/0009-9236(95)90177-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1016/0009-9236(95)90177-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1016/0009-9236(95)90177-9'


 

This table displays all metadata directly associated to this object as RDF triples.

259 TRIPLES      22 PREDICATES      132 URIs      114 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1016/0009-9236(95)90177-9 schema:about N00d07c39bf1241ed853e3fb791ef4fbd
2 N09ebfb7db1024415b0f7b7c81b235d87
3 N2f34d79925d54a42b605f6caf90b7823
4 N61e07456161b4566a8ae5a4294702649
5 N8844f49e92a44224bbb775d760e2c324
6 N88ab5ab4b5ba4a0d908a6179180183cc
7 N8cc6fce34464430989773c39a09c7c92
8 Nba1b9f20d9a848b78e3a364374c094a7
9 Nc1120b64e9924c32a4148ebeb2d1d663
10 Nc46b9df2e7f342d88fc9fae0cd6afd78
11 Nf8f1c24da6a6400d9c5728e29863e8e8
12 anzsrc-for:11
13 anzsrc-for:1103
14 schema:author N2220c13881ae400dab86f9f604b3eaea
15 schema:citation sg:pub.10.1007/bf01064422
16 sg:pub.10.1007/bf01080874
17 sg:pub.10.1007/bf01620551
18 sg:pub.10.1038/clpt.1988.106
19 sg:pub.10.1038/clpt.1989.41
20 sg:pub.10.1038/clpt.1994.174
21 sg:pub.10.2165/00003088-198814010-00001
22 sg:pub.10.2165/00003088-199018030-00006
23 sg:pub.10.2165/00003088-199120060-00005
24 sg:pub.10.2165/00003088-199120060-00006
25 schema:datePublished 1995-11
26 schema:datePublishedReg 1995-11-01
27 schema:description The purpose of this study was to model pharmacodynamically the reversal of midazolam sedation with flumazenil. Ten human volunteers underwent four different sessions. In session 1, individual midazolam pharmacokinetics and electroencephalographic pharmacodynamics were determined. In sessions 2 and 3, a computer-controlled infusion of midazolam with individual volunteer pharmacokinetic data was administered, targeting a plasma concentration corresponding to a light or deep level of sedation (20% or 80% of the maximal midazolam electroencephalographic effect) for a period of 210 minutes. After obtaining a stable electroencephalographic effect and constant midazolam plasma concentrations, a zero-order infusion of flumazenil was started until complete reversal of midazolam electroencephalographic effect was obtained. The flumazenil infusion was then stopped and the volunteer was allowed to resedate because of the constant midazolam drug effect. The electroencephalographic response was measured during a 180-minute period and analyzed by aperiodic analysis and fast-Fourier transforms. In session 4, a midazolam plasma concentration corresponding to a deep level of sedation was targeted for 210 minutes to examine for the possible development of acute tolerance. No flumazenil was given in session 4. For a light sedation level, with a mean midazolam plasma concentration of 160 +/- 64 ng/ml, the mean half-life of the equilibration rate constant of flumazenil reversal is 5.0 +/- 2.5 minutes, and the mean effect site concentration causing 50% of Emax is 13.7 +/- 5.8 ng/ml. For a deep level of sedation, with a mean midazolam plasma concentration of 551 +/- 196 ng/ml, the mean half-life of the equilibration rate constant is 3.9 +/- 1.5 minutes, and the mean effect site concentration causing 50% of Emax is 20.6 +/- 6.8 ng/ml. This study provides an estimate of the magnitude of the blood/central nervous system equilibration delay for flumazenil antagonism of midazolam sedation and further defines the usefulness of the electroencephalogram as a measure of midazolam pharmacodynamic effect.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf Ne048fb7032bd422ba6bd951c8cc2c34c
32 Nfa0c8f705572408cbb0e25df996acf36
33 sg:journal.1017409
34 schema:keywords Emax
35 acute tolerance
36 analysis
37 antagonism
38 aperiodic analysis
39 blood/central nervous system equilibration delay
40 central nervous system equilibration delay
41 complete reversal
42 computer-controlled infusion
43 concentration
44 constant midazolam drug effect
45 constant midazolam plasma concentrations
46 constants
47 data
48 deep levels
49 delay
50 development
51 different sessions
52 drug effects
53 effect
54 effect site concentration
55 electroencephalogram
56 electroencephalographic effects
57 electroencephalographic pharmacodynamics
58 electroencephalographic responses
59 equilibration delay
60 equilibration rate
61 equilibration rate constant
62 estimates
63 fast-Fourier transform
64 flumazenil
65 flumazenil antagonism
66 flumazenil infusion
67 flumazenil reversal
68 healthy volunteers
69 human volunteers
70 individual midazolam pharmacokinetics
71 individual volunteer pharmacokinetic data
72 infusion
73 levels
74 lighter sedation levels
75 magnitude
76 mean effect site concentration
77 mean midazolam plasma concentration
78 measures
79 midazolam
80 midazolam drug effect
81 midazolam electroencephalographic effect
82 midazolam pharmacodynamic effect
83 midazolam pharmacokinetics
84 midazolam plasma concentrations
85 midazolam sedation
86 minutes
87 modeling
88 nervous system equilibration delay
89 period
90 pharmacodynamic effects
91 pharmacodynamic modeling
92 pharmacodynamics
93 pharmacokinetic data
94 pharmacokinetics
95 plasma concentrations
96 possible development
97 purpose
98 rate
99 rate constants
100 response
101 reversal
102 sedation
103 sedation level
104 session 1
105 session 2
106 session 4
107 sessions
108 site concentration
109 stable electroencephalographic effect
110 study
111 system equilibration delay
112 tolerance
113 transform
114 usefulness
115 volunteer pharmacokinetic data
116 volunteers
117 zero-order infusion
118 schema:name Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam
119 schema:pagination 567-582
120 schema:productId N3c683306587041c0a49888739347273d
121 N4dedcc7fb5604e37b32a5353daa63272
122 N651b472b07354a019456e745cfca5835
123 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035614341
124 https://doi.org/10.1016/0009-9236(95)90177-9
125 schema:sdDatePublished 2022-01-01T18:07
126 schema:sdLicense https://scigraph.springernature.com/explorer/license/
127 schema:sdPublisher N8522d4a55e4e474cbf27d0c6736682d6
128 schema:url https://doi.org/10.1016/0009-9236(95)90177-9
129 sgo:license sg:explorer/license/
130 sgo:sdDataset articles
131 rdf:type schema:ScholarlyArticle
132 N001c0c9ae6a24cc6beea63aeadb1a297 schema:affiliation grid-institutes:grid.223827.e
133 schema:familyName Lemmens
134 schema:givenName Hendrikus L.M.
135 rdf:type schema:Person
136 N00d07c39bf1241ed853e3fb791ef4fbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Middle Aged
138 rdf:type schema:DefinedTerm
139 N09ebfb7db1024415b0f7b7c81b235d87 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Midazolam
141 rdf:type schema:DefinedTerm
142 N2220c13881ae400dab86f9f604b3eaea rdf:first sg:person.01352532122.58
143 rdf:rest N79352650623a446eadc9a62222102919
144 N2f34d79925d54a42b605f6caf90b7823 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Flumazenil
146 rdf:type schema:DefinedTerm
147 N3c683306587041c0a49888739347273d schema:name pubmed_id
148 schema:value 7586951
149 rdf:type schema:PropertyValue
150 N4dedcc7fb5604e37b32a5353daa63272 schema:name doi
151 schema:value 10.1016/0009-9236(95)90177-9
152 rdf:type schema:PropertyValue
153 N53c5e096128647c78b1bf7e495d03e46 rdf:first sg:person.0727474353.23
154 rdf:rest rdf:nil
155 N61e07456161b4566a8ae5a4294702649 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Fourier Analysis
157 rdf:type schema:DefinedTerm
158 N651b472b07354a019456e745cfca5835 schema:name dimensions_id
159 schema:value pub.1035614341
160 rdf:type schema:PropertyValue
161 N79352650623a446eadc9a62222102919 rdf:first N001c0c9ae6a24cc6beea63aeadb1a297
162 rdf:rest Ndf94c082cddc4a17a1c0019d9d312acc
163 N8522d4a55e4e474cbf27d0c6736682d6 schema:name Springer Nature - SN SciGraph project
164 rdf:type schema:Organization
165 N8844f49e92a44224bbb775d760e2c324 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Humans
167 rdf:type schema:DefinedTerm
168 N88ab5ab4b5ba4a0d908a6179180183cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Electroencephalography
170 rdf:type schema:DefinedTerm
171 N89e2b43cd18b4ef8ab981e85e9f9533b schema:affiliation grid-institutes:grid.223827.e
172 schema:familyName Egan
173 schema:givenName Talmage E.
174 rdf:type schema:Person
175 N8cc6fce34464430989773c39a09c7c92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Models, Biological
177 rdf:type schema:DefinedTerm
178 Nb1b962695f5c4ceda4eb158604b892ac rdf:first sg:person.01053425453.16
179 rdf:rest N53c5e096128647c78b1bf7e495d03e46
180 Nba1b9f20d9a848b78e3a364374c094a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name GABA Modulators
182 rdf:type schema:DefinedTerm
183 Nc1120b64e9924c32a4148ebeb2d1d663 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Male
185 rdf:type schema:DefinedTerm
186 Nc46b9df2e7f342d88fc9fae0cd6afd78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Adult
188 rdf:type schema:DefinedTerm
189 Ndf94c082cddc4a17a1c0019d9d312acc rdf:first N89e2b43cd18b4ef8ab981e85e9f9533b
190 rdf:rest Nb1b962695f5c4ceda4eb158604b892ac
191 Ne048fb7032bd422ba6bd951c8cc2c34c schema:issueNumber 5
192 rdf:type schema:PublicationIssue
193 Nf8f1c24da6a6400d9c5728e29863e8e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Hypnotics and Sedatives
195 rdf:type schema:DefinedTerm
196 Nfa0c8f705572408cbb0e25df996acf36 schema:volumeNumber 58
197 rdf:type schema:PublicationVolume
198 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
199 schema:name Medical and Health Sciences
200 rdf:type schema:DefinedTerm
201 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
202 schema:name Clinical Sciences
203 rdf:type schema:DefinedTerm
204 sg:journal.1017409 schema:issn 0009-9236
205 1532-6535
206 schema:name Clinical Pharmacology & Therapeutics
207 schema:publisher Springer Nature
208 rdf:type schema:Periodical
209 sg:person.01053425453.16 schema:affiliation grid-institutes:grid.223827.e
210 schema:familyName Shafer
211 schema:givenName Steven L.
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053425453.16
213 rdf:type schema:Person
214 sg:person.01352532122.58 schema:affiliation grid-institutes:grid.223827.e
215 schema:familyName Fiset
216 schema:givenName Pierre
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352532122.58
218 rdf:type schema:Person
219 sg:person.0727474353.23 schema:affiliation grid-institutes:grid.223827.e
220 schema:familyName Stanski
221 schema:givenName Donald R.
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727474353.23
223 rdf:type schema:Person
224 sg:pub.10.1007/bf01064422 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020922126
225 https://doi.org/10.1007/bf01064422
226 rdf:type schema:CreativeWork
227 sg:pub.10.1007/bf01080874 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022518677
228 https://doi.org/10.1007/bf01080874
229 rdf:type schema:CreativeWork
230 sg:pub.10.1007/bf01620551 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005966643
231 https://doi.org/10.1007/bf01620551
232 rdf:type schema:CreativeWork
233 sg:pub.10.1038/clpt.1988.106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006636807
234 https://doi.org/10.1038/clpt.1988.106
235 rdf:type schema:CreativeWork
236 sg:pub.10.1038/clpt.1989.41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044118057
237 https://doi.org/10.1038/clpt.1989.41
238 rdf:type schema:CreativeWork
239 sg:pub.10.1038/clpt.1994.174 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009681062
240 https://doi.org/10.1038/clpt.1994.174
241 rdf:type schema:CreativeWork
242 sg:pub.10.2165/00003088-198814010-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045191439
243 https://doi.org/10.2165/00003088-198814010-00001
244 rdf:type schema:CreativeWork
245 sg:pub.10.2165/00003088-199018030-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045679441
246 https://doi.org/10.2165/00003088-199018030-00006
247 rdf:type schema:CreativeWork
248 sg:pub.10.2165/00003088-199120060-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047792911
249 https://doi.org/10.2165/00003088-199120060-00005
250 rdf:type schema:CreativeWork
251 sg:pub.10.2165/00003088-199120060-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042979892
252 https://doi.org/10.2165/00003088-199120060-00006
253 rdf:type schema:CreativeWork
254 grid-institutes:grid.223827.e schema:alternateName University of Utah Department of Anesthesia Salt Lake City Utah.
255 schema:name McGill University Department of Anesthesia Montreal Quebec Canada
256 Palo Alto Veterans Administration Medical Center Palo Alto Calif.
257 Stanford University Department of Anesthesia
258 University of Utah Department of Anesthesia Salt Lake City Utah.
259 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...